Foresite Labs | LinkedIn (original) (raw)

Biotechnology

San Francisco, California 4,584 followers

A center for entrepreneurial innovation at the nexus of data science and healthcare

Discover all 50 employees

About us

Foresite Labs incubates companies that will address some of our greatest unmet medical needs. Their experienced team of scientists, engineers, and operators believes that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients. Through its incubation platform, Foresite Labs is dismantling the barriers faced by visionary entrepreneurs and their companies as they seek to re-invent healthcare. Foresite Labs Values Truth over progression: We follow the science, pursuing ideas that are grounded in data and abandoning them when not supported by the evidence. Take good risks: Our culture values informed risk-taking: good decisions are celebrated even when they result in bad outcomes. Everyone feels safe to contribute ideas and to learn from failure. Single accountable person: The project team lead is accountable for all decisions and for maintaining transparency and information flow within the team; we trust the project teams. The Review Committee unlocks capital and sets directions. Simplicity and Focus: “Companies die from indigestion, not starvation” (Bill Hewlett) We will focus on a few ideas aggressively and minimize all other distractions. Everyone will have a few key goals that have measurable outcomes. Respect and Community: Our employees are our greatest asset; everyone invests in creating an environment of collaboration and respect. We support their careers and career development whether they stay, go to a Labs company, or end up somewhere else.

Industry

Biotechnology

Company size

11-50 employees

Headquarters

San Francisco, California

Type

Privately Held

Founded

2019

Locations

Employees at Foresite Labs

Updates

Congratulations to our venture partner Scott McIsaac on his appointment to the Life Sciences Research Foundation advisory board! This prestigious program identifies exceptional postdoc scientists and arranges funding from biotech and pharma companies, foundations, and philanthropic individuals for the duration of their awards. Scott is an alumnus of this program, as is David Baker, co-founder of our incubated company Xaira Therapeutics and newly minted Nobel laureate. Proud of you, Scott! We look forward to seeing what you accomplish with this impressive organization.
Welcoming Scott McIsaac to the Advisory Board of the Life Sciences Research Foundation!
Our co-founder and CEO Vik Bajaj is at #HLTH2024 asking the question: When will AI enable new ways of delivering care that improve outcomes and reduce costs in truly dramatic and unexpected ways? Listen for his take from Las Vegas. #healthcareonLinkedIn
Foresite Labs reposted this
We're excited to share that Mary Helen Black has been promoted to SVP and head of human genomics at Foresite Labs! Mary Helen has been a driver behind our efforts in building ML/AI analytics capabilities that support target discovery for our incubated companies. She also leads and contributes to multiple stealth company incubation efforts in the precision therapeutics and health care delivery space. We're so grateful for her work over the past two years, and excited to see what she and her team accomplish in the future!
This is incredible news! We are so honored to be working with David Baker - now a Nobel Laureate! - in his role as co-founder of Xaira Therapeutics, a Foresite Labs co-incubation with ARCH Venture Partners. The breakthroughs from these three scientists have provided the foundation for the work being done at Xaira under the leadership of Marc Tessier-Lavigne. Today, we celebrate! 🥳
BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 Nobel Prize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.” The Nobel Prize in Chemistry 2024 is about proteins, life’s ingenious chemical tools. David Baker has succeeded with the almost impossible feat of building entirely new kinds of proteins. Demis Hassabis and John Jumper have developed an AI model to solve a 50-year-old problem: predicting proteins’ complex structures. These discoveries hold enormous potential. The diversity of life testifies to proteins’ amazing capacity as chemical tools. They control and drive all the chemical reactions that together are the basis of life. Proteins also function as hormones, signal substances, antibodies and the building blocks of different tissues. Proteins generally consist of 20 different amino acids, which can be described as life’s building blocks. In 2003, David Baker succeeded in using these blocks to design a new protein that was unlike any other protein. Since then, his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors. The second discovery concerns the prediction of protein structures. In proteins, amino acids are linked together in long strings that fold up to make a three-dimensional structure, which is decisive for the protein’s function. Since the 1970s, researchers had tried to predict protein structures from amino acid sequences, but this was notoriously difficult. However, four years ago, there was a stunning breakthrough. In 2020, Demis Hassabis and John Jumper presented an AI model called AlphaFold2. With its help, they have been able to predict the structure of virtually all the 200 million proteins that researchers have identified. Since their breakthrough, AlphaFold2 has been used by more than two million people from 190 countries. Among a myriad of scientific applications, researchers can now better understand antibiotic resistance and create images of enzymes that can decompose plastic. Life could not exist without proteins. That we can now predict protein structures and design our own proteins confers the greatest benefit to humankind. Learn more Press release: https://bit.ly/3TM8oVsPopular information: https://bit.ly/3XYHZGpAdvanced information: https://bit.ly/4ewMBta
We're excited to share that Mary Helen Black has been promoted to SVP and head of human genomics at Foresite Labs! Mary Helen has been a driver behind our efforts in building ML/AI analytics capabilities that support target discovery for our incubated companies. She also leads and contributes to multiple stealth company incubation efforts in the precision therapeutics and health care delivery space. We're so grateful for her work over the past two years, and excited to see what she and her team accomplish in the future!
Excellent news! We are delighted that Xaira Therapeutics has landed such a talented CSO so soon after launch. We can't wait to see what Debbie Law accomplishes, working with Marc Tessier-Lavigne & team as they harness AI to transform how we treat disease.
We are so pleased to announce that Debbie Law has joined Xaira as our chief scientific officer! This is a big moment for our company. Debbie's background is uniquely suited for this challenge, and to say we are thrilled that she chose to join us is quite an understatement! Debbie most recently served as senior vice president and head of Bristol Myers Squibb’s Non-clinical Research and Discovery Biotherapeutics organizations. Prior to BMS, she spent time at life science companies including Janssen and Merck, and served as CSO at Jounce Therapeutics and Ablynx NV. Debbie completed her undergraduate degree at the University of Glasgow and earned her Doctor of Philosophy (DPhil) in immunology from the University of Oxford. She will be reporting to our CEO, Marc Tessier-Lavigne. Debbie lives in Hillsborough, and in her free time enjoys walking and watching zombie movies 🧟♂️ 🧟♀️
We're thrilled with the recognition for Xaira Therapeutics on the Endpoints 11 list! Our CEO Vik Bajaj joined Xaira's CEO Marc Tessier-Lavigne last night in Boston at the awards ceremony. It's been an incredible start for Xaira since the launch in April after co-incubating the firm with ARCH Venture Partners. Congrats to all on the list!
Last night in Boston, the Endpoints News team unveiled the Endpoints 11 — our picks for the most exciting biotech startups of 2024. This year’s list includes several artificial intelligence startups trying to reinvent drug R&D, though doing so with very different approaches. It highlights the growth of China’s biotech industry, despite the country’s tensions with the US. Four of the winners are taking new approaches to huge disease categories including inflammation and immunology, obesity and neuroscience. And others are working on advanced technologies for rare ailments, operating at the forefront of editing biology. Congratulations to: Lifordi Immunotherapeutics, Inc., Mirador Therapeutics, Formation Bio, Xaira Therapeutics, Medilink International, Iambic Therapeutics, Ascidian Therapeutics, Capstan Therapeutics, Seaport Therapeutics, Metsera, Cardurion PharmaceuticalsRead our profiles of this year’s winners here.
The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry endpts.com

Join now to see what you are missing

Join now

Foresite Labs | LinkedIn (original) (raw)

Biotechnology

San Francisco, California 4,584 followers

A center for entrepreneurial innovation at the nexus of data science and healthcare

About us

Locations

Employees at Foresite Labs

Updates

Join now to see what you are missing

Similar pages

Browse jobs